Last reviewed · How we verify
Clarythromycin
Clarythromycin, marketed by CPL Associates, is an established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and long-term revenue generation. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | Clarythromycin |
|---|---|
| Sponsor | CPL Associates |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) (PHASE1)
- Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole (PHASE4)
- Effects of H.Pylori Eradication on Microbiome (PHASE4)
- Helicobacter Eradication Relief of Dyspeptic Symptoms (PHASE3)
- Outpatient Registry Trial of Respiratory Tract Infections in Adults (PHASE4)
- H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |